Modulation of extracellular matrix in cancer is associated with enhanced tumor cell targeting by bacteriophage vectors

Molecular Cancer

Volumn 14, Issue 1, 2015, Pages

  Yata, Teerapong ^a,b   Lee, Eugene L Q ^a   Suwan, Keittisak ^a   Syed, Nelofer ^a   Asavarut, Paladd ^a   Hajitou, Amin ^a,c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT AGENCY   (Thailand)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Bacteriophage; Cancer gene therapy; Extracellular matrix; Multicellular tumor spheroids

Indexed keywords

COLLAGEN TYPE 1; COLLAGENASE; FIBRONECTIN; HYALURONIC ACID; HYALURONIDASE; LAMININ; PARVOVIRUS VECTOR; CD51 ANTIGEN; GANCICLOVIR; HYALURONOGLUCOSAMINIDASE; LOSARTAN;

ADSORPTION KINETICS; ANIMAL CELL; ARTICLE; BREAST CANCER CELL LINE; CANCER GENE THERAPY; CHEMICAL COMPOSITION; CONTROLLED STUDY; DEGRADATION; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX DEGRADATION; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSDUCTION; GLIOBLASTOMA CELL LINE; GLIOSARCOMA; HUMAN; HUMAN CELL; INTERNALIZATION; MELANOMA CELL LINE; MOUSE; MULTICELLULAR TUMOR SPHEROID MODEL; NONHUMAN; PROSTATE CANCER CELL LINE; TUMOR CELL; TUMOR CELL LINE; TUMOR MODEL; TUMOR SPHEROID; VIRUS GENOME; ANIMAL; BACTERIOPHAGE; CELL DEATH; CELL SURVIVAL; DEPENDOPARVOVIRUS; DIFFUSION; DRUG EFFECTS; ENDOCYTOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE VECTOR; METABOLISM; MULTICELLULAR SPHEROID; NEOPLASM; PATHOLOGY; RAT;

ADENO-ASSOCIATED VIRUS;

ANIMALS; BACTERIOPHAGES; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; COLLAGENASES; DEPENDOVIRUS; DIFFUSION; ENDOCYTOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FIBRONECTINS; GANCICLOVIR; GENE EXPRESSION; GENETIC VECTORS; HUMANS; HYALURONOGLUCOSAMINIDASE; INTEGRIN ALPHAV; LAMININ; LOSARTAN; NEOPLASMS; RATS; SPHEROIDS, CELLULAR; TRANSDUCTION, GENETIC;

EID: 84930618067     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/s12943-015-0383-4     Document Type: Article

References (56)

1. Khan J, Wei JS, Ringner M, Saal LH, Ladanyi M, Westermann F, et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med. 2001;7:673-9.
2. Romano G, Pacilio C, Giordano A. Gene transfer technology in therapy: current applications and future goals. Stem Cells. 1999;17:191-202.
3. Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2012 - an update. J Gene Med. 2013;15:65-77.
4. Allen C, Vongpunsawad S, Nakamura T, James CD, Schroeder M, Cattaneo R, et al. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. Cancer Res. 2006;66:11840-50.
5. Hajitou A. Targeted systemic gene therapy and molecular imaging of cancer contribution of the vascular-targeted AAVP vector. Adv Genet. 2010;69:65-82.
6. Hajitou A, Trepel M, Lilley CE, Soghomonyan S, Alauddin MM, Marini 3rd FC, et al. A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell. 2006;125:385-98.
7. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998;279:377-80.
8. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, et al. Tumor regression by targeted gene delivery to the neovasculature. Science. 2002;296:2404-7.
9. Paoloni MC, Tandle A, Mazcko C, Hanna E, Kachala S, Leblanc A, et al. Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature. PLoS One. 2009;4:e4972.
10. Ozdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014;25:719-34.
11. Cairns R, Papandreou I, Denko N. Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Molecular Cancer Res. 2006;4:61-70.
12. Lu D, Wientjes MG, Lu Z, Au JL. Tumor priming enhances delivery and efficacy of nanomedicines. J Pharmacol Exp Ther. 2007;322:80-8.
13. Magzoub M, Jin S, Verkman AS. Enhanced macromolecule diffusion deep in tumors after enzymatic digestion of extracellular matrix collagen and its associated proteoglycan decorin. FASEB J. 2008;22:276-84.
14. McKee TD, Grandi P, Mok W, Alexandrakis G, Insin N, Zimmer JP, et al. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res. 2006;66:2509-13.
15. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 2000;60:2497-503.
16. Yata T, Lee KY, Dharakul T, Songsivilai S, Bismarck A, Mintz PJ, et al. Hybrid Nanomaterial Complexes for Advanced Phage-guided Gene Delivery. Molecular Therapy Nucleic acids. 2014;3, e185.
17. Mulgrew K, Kinneer K, Yao XT, Ward BK, Damschroder MM, Walsh B, et al. Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin. Mol Cancer Ther. 2006;5:3122-9.
18. Mattern RH, Read SB, Pierschbacher MD, Sze CI, Eliceiri BP, Kruse CA. Glioma cell integrin expression and their interactions with integrin antagonists: Research Article. Cancer Therapy. 2005;3A:325-40.
19. Zheng DQ, Woodard AS, Tallini G, Languino LR. Substrate specificity of alpha(v)beta(3) integrin-mediated cell migration and phosphatidylinositol 3-kinase/AKT pathway activation. J Biol Chem. 2000;275:24565-74.
20. Adachi Y, Lakka SS, Chandrasekar N, Yanamandra N, Gondi CS, Mohanam S, et al. Down-regulation of integrin alpha(v)beta(3) expression and integrin-mediated signaling in glioma cells by adenovirus-mediated transfer of antisense urokinase-type plasminogen activator receptor (uPAR) and sense p16 genes. J Biol Chem. 2001;276:47171-7.
21. Monferran S, Skuli N, Delmas C, Favre G, Bonnet J, Cohen-Jonathan-Moyal E, et al. Alphavbeta3 and alphavbeta5 integrins control glioma cell response to ionising radiation through ILK and RhoB. Int J Cancer J Int du Cancer. 2008;123:357-64.
22. Sloan EK, Pouliot N, Stanley KL, Chia J, Moseley JM, Hards DK, et al. Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res. 2006;8:R20.
23. Kunz-Schughart LA. Multicellular tumor spheroids: intermediates between monolayer culture and in vivo tumor. Cell Biol Int. 1999;23:157-61.
24. Trepel M, Stoneham CA, Eleftherohorinou H, Mazarakis ND, Pasqualini R, Arap W, et al. A heterotypic bystander effect for tumor cell killing after adeno-associated virus/phage-mediated, vascular-targeted suicide gene transfer. Mol Cancer Ther. 2009;8:2383-91.
25. Diop-Frimpong B, Chauhan VP, Krane S, Boucher Y, Jain RK. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc Natl Acad Sci U S A. 2011;108:2909-14.
26. Danen EH, Sonneveld P, Brakebusch C, Fassler R, Sonnenberg A. The fibronectin-binding integrins alpha5beta1 and alphavbeta3 differentially modulate RhoA-GTP loading, organization of cell matrix adhesions, and fibronectin fibrillogenesis. J Cell Biol. 2002;159:1071-86.
27. Montgomery AM, Reisfeld RA, Cheresh DA. Integrin alpha v beta 3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc Natl Acad Sci U S A. 1994;91:8856-60.
28. Stoneham CA, Hollinshead M, Hajitou A. Clathrin-mediated endocytosis and subsequent endo-lysosomal trafficking of adeno-associated virus/phage. J Biol Chem. 2012;287:35849-59.
29. Eikenes L, Bruland OS, Brekken C, Davies Cde L. Collagenase increases the transcapillary pressure gradient and improves the uptake and distribution of monoclonal antibodies in human osteosarcoma xenografts. Cancer Res. 2004;64:4768-73.
30. Hurst LC, Badalamente MA, Hentz VR, Hotchkiss RN, Kaplan FT, Meals RA, et al. Injectable collagenase clostridium histolyticum for Dupuytren's contracture. N Engl J Med. 2009;361:968-79.
31. Diener B, Carrick Jr L, Berk RS. In vivo studies with collagenase from Pseudomonas aeruginosa. Infect Immun. 1973;7:212-7.
32. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol. 2012;196:395-406.
33. Duffy MJ, McCarthy K. Matrix metalloproteinases in cancer: prognostic markers and targets for therapy (review). Int J Oncol. 1998;12:1343-8.
34. Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, Lisi MT, et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med. 2007;13:204-10.
35. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006;312:117-21.
36. Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet. 1995;346:1403-7.
37. Jakowlew SB. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev. 2006;25:435-57.
38. Choi IK, Strauss R, Richter M, Yun CO, Lieber A. Strategies to increase drug penetration in solid tumors. Frontiers Oncology. 2013;3:193.
39. Yi M, Ruoslahti E. A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis. Proc Natl Acad Sci U S A. 2001;98:620-4.
40. Jia Y, Zeng ZZ, Markwart SM, Rockwood KF, Ignatoski KM, Ethier SP, et al. Integrin fibronectin receptors in matrix metalloproteinase-1-dependent invasion by breast cancer and mammary epithelial cells. Cancer Res. 2004;64:8674-81.
41. Borthwick LA, Gardner A, De Soyza A, Mann DA, Fisher AJ. Transforming Growth Factor-beta1 (TGF-beta1) Driven Epithelial to Mesenchymal Transition (EMT) is Accentuated by Tumour Necrosis Factor alpha (TNFalpha) via Crosstalk Between the SMAD and NF-kappaB Pathways. Cancer Micro Environ. 2012;5:45-57.
42. Kuriyama N, Kuriyama H, Julin CM, Lamborn K, Israel MA. Pretreatment with protease is a useful experimental strategy for enhancing adenovirus-mediated cancer gene therapy. Hum Gene Ther. 2000;11:2219-30.
43. Maroko PR, Davidson DM, Libby P, Hagan AD, Braunwald E. Effects of hyaluronidase administration on myocardial ischemic injury in acute infarction. A preliminary study in 24 patients. Ann Intern Med. 1975;82:516-20.
44. Stern R. Hyaluronidases in cancer biology. Semin Cancer Biol. 2008;18:275-80.
45. Eberhart AH, Weiler CR, Erie JC. Angioedema related to the use of hyaluronidase in cataract surgery. Am J Ophthalmol. 2004;138:142-3.
46. Bookbinder LH, Hofer A, Haller MF, Zepeda ML, Keller GA, Lim JE, et al. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Controlled Release. 2006;114:230-41.
47. Yocum RC, Kennard D, Heiner LS. Assessment and implication of the allergic sensitivity to a single dose of recombinant human hyaluronidase injection: a double-blind, placebo-controlled clinical trial. J Infusion Nursing. 2007;30:293-9.
48. Udabage L, Brownlee GR, Waltham M, Blick T, Walker EC, Heldin P, et al. Antisense-mediated suppression of hyaluronan synthase 2 inhibits the tumorigenesis and progression of breast cancer. Cancer Res. 2005;65:6139-50.
49. Lokeshwar VB, Lopez LE, Munoz D, Chi A, Shirodkar SP, Lokeshwar SD, et al. Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells. Cancer Res. 2010;70:2613-23.
50. Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA. Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol. 2010;148:3-15.
51. Demicheli R, Retsky MW, Hrushesky WJ, Baum M, Gukas ID. The effects of surgery on tumor growth: a century of investigations. Annals Oncology. 2008;19:1821-8.
52. Flintoft L. Breast cancer: Recurrence. Nat Rev Cancer. 2003;3:718.
53. Pothacharoen P, Siriaunkgul S, Ong-Chai S, Supabandhu J, Kumja P, Wanaphirak C, et al. Raised serum chondroitin sulfate epitope level in ovarian epithelial cancer. J Biochem. 2006;140:517-24.
54. Hajitou A, Rangel R, Trepel M, Soghomonyan S, Gelovani JG, Alauddin MM, et al. Design and construction of targeted AAVP vectors for mammalian cell transduction. Nat Protoc. 2007;2:523-31.
55. Jaye DL, Geigerman CM, Fuller RE, Akyildiz A, Parkos CA. Direct fluorochrome labeling of phage display library clones for studying binding specificities: applications in flow cytometry and fluorescence microscopy. J Immunol Methods. 2004;295:119-27.
56. Vinci M, Gowan S, Boxall F, Patterson L, Zimmermann M, Court W, et al. Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol. 2012;10:29.